Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma
Open Access
- 1 February 2015
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 13 (1) , 1-10
Abstract
Deubiquitinases, such as CYLD, A20 and Cezanne, have emerged as negative regulators that balance the strength and duration of NF-κB signaling through feedback mechanisms. However, how these serial feedback loops are simultaneously disrupted in cancer remains unclear. The purpose of this study is to investigate the correlation of Cezanne expression with clinicopathological/prognostic value in hepatocellular carcinoma (HCC). The expression levels of Cezanne and matrix metallopeptidase 9 (MMP-9) were assessed by immunohistochemistry in 230 HCC specimens. The correlation between expression of Cezanne and MMP-9, clinicopathological/prognostic value in hepatocellular carcinoma was examined. Cezanne reduction in HCC was significantly associated with larger tumor, satellite nodule, vascular invasion, TNM stage, BCLC stage and early recurrence. Kaplan-Meier analysis showed that Cezanne was a great predictive factor for overall survival (OS) and time to recurrence (TTR). The expression of Cezanne was decreased in TNM and BCLC stage-dependent manner. In addition, Cezanne reduction was associated with poor prognosis in patients subgroups stratified by tumor size, tumor differentiation, TNM stage and BCLC stage. Moreover, Cezanne was negatively associated with MMP-9 among 230 HCC samples. Patients who had Cezanne downregulation, in which cancer cells showed high invasiveness, had shorter TTR and poor OS. Furthermore, the coindex of Cezanne and preoperative serum AFP levels was significantly correlated with OS and TTR. Cezanne has a pivotal role in tumor progression and prognosis, and may act as a potential prognostic biomarker for survival in HCC patients.Keywords
This publication has 33 references indexed in Scilit:
- Molecular Pathways: The Complex Roles of Inflammation Pathways in the Development and Treatment of Liver CancerClinical Cancer Research, 2013
- The complexity of NF-κB signaling in inflammation and cancerMolecular Cancer, 2013
- NF-κB and STAT3 – key players in liver inflammation and cancerCell Research, 2010
- Pivotal Role of mTOR Signaling in Hepatocellular CarcinomaGastroenterology, 2008
- Molecular mechanisms of hepatocellular carcinomaHepatology, 2008
- Molecular targeted therapies in hepatocellular carcinoma†Hepatology, 2008
- Inflammation and cancer: Role of nuclear factor‐kappaB activationCancer Science, 2008
- Phase III Randomized Controlled Trial Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma Treated With Nolatrexed or DoxorubicinJournal of Clinical Oncology, 2007
- Hepatocellular Carcinoma: Epidemiology and Molecular CarcinogenesisGastroenterology, 2007
- De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signallingNature, 2004